nejm semaglutide ckd Updates in Medicine | 🩺 Oral Cuts CV Risk in High-Risk T2DM – SOUL Trial (NEJM, Mar 2025) 🔗 Original article link in bio 📌 Key Highlights: 🔹 Long-term kidney outcomes of semaglutide

Reta: Enhanced Energy Metabolism The inclusion of glucagon receptor activity sets Reta apart

Status: Phase 3 trials are ongoing, with full results and potential approval pathways expected in 2026

Its dermatologist-approved formula ensures visible brightening results without compromising skin health

(11) In an analysis of military medical records, published in JAMA , researchers found that rates of Hashimotos thyroiditis were significantly lower in Black people and Asian people and Pacific Islanders, while being much higher in white people

She Pushed Through Her "GLP-1 Plateatu" and Lost 55 Pounds on Ozempic with These 10 Tips Has your weight loss progress paused while on Ozempic